Clinical Trial Update: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing NS-018 to best available therapy in myelofibrosis was terminated, and results have been posted on May 23, 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• NS-018

Snippet

Sponsor: NS Pharma, Inc. | Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Status: TERMINATED | Results posted: 2025-05-23